Implications of Sphingolipids on Aging and Age-Related Diseases

Shengxin Li¹,² and Hyun-Eui Kim¹,²*

¹Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, TX, United States; ²Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Aging is a process leading to a progressive loss of physiological integrity and homeostasis, and a primary risk factor for many late-onset chronic diseases. The mechanisms underlying aging have long piqued the curiosity of scientists. However, the idea that aging is a biological process susceptible to genetic manipulation was not well established until the discovery that the inhibition of insulin/IGF-1 signaling extended the lifespan of C. elegans. Although aging is a complex multisystem process, López-Otín et al. described aging in reference to nine hallmarks of aging. These nine hallmarks include: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Due to recent advances in lipidomic, investigation into the role of lipids in biological aging has intensified, particularly the role of sphingolipids (SL). SLs are a diverse group of lipids originating from the Endoplasmic Reticulum (ER) and can be modified to create a vastly diverse group of bioactive metabolites that regulate almost every major cellular process, including cell cycle regulation, senescence, proliferation, and apoptosis. Although SL biology reaches all nine hallmarks of aging, its contribution to each hallmark is disproportionate. In this review, we will discuss in detail the major contributions of SLs to the hallmarks of aging and age-related diseases while also summarizing the importance of their other minor but integral contributions.

Keywords: aging, lipids, sphingolipids, ceramide, age-related diseases, hallmarks of aging

INTRODUCTION

Life expectancy has significantly increased over the last two hundred years due to the increase in quality of water, hygiene, and modern medicine. In recent decades, research in aging has grown in popularity due to the discovery of the notion that aging, like many other biological functions, can be subjected to genetic and environmental interventions (Kenyon, 2010). Several hallmarks of aging have been identified, highlighting the importance of several key physiological processes in aging. These hallmarks include deregulated nutrient sensing, cellular senescence, loss of proteostasis, genetic instability, altered cellular communication, mitochondria dysfunction, and stem cell exhaustion (López-Otín et al., 2013). One field that has intensified over the years is the study of lipids and their roles in aging.

Lipids are a large group of diverse macromolecules involved in key biological functions including serving as key structural components of cell and organelle membranes, a source of stored metabolic energy and signaling intermediates in various signaling pathways. There is a diverse structural variety among lipids, encompassing fatty acid and their derivatives to sterol-containing metabolites. Lipids are broken down into eight categories as defined by the International Lipid Classification and...
Nomenclature Committee (ILCNC). These include fatty acyls (FA), glycerolipids (GL), glycerophospholipids (GP), sphingolipids (SL), sterol lipids (ST), phenol lipids (PR), saccharolipids (SaL) and polyketides (PK) (Fahy et al., 2009). Studies have unveiled unique relationships between lipid profiles and aging in many of the model organisms including humans (Bustos and Partridge, 2017).

Before the early 1990s, the field of lipid studies was rooted exclusively in their functions in cellular structure and energy metabolism. However, in 1992, the discovery that diacylglycerol (DAG) directly activates protein kinase C (PKC) (Nishizuka, 1992) provided the spark that was needed to ignite the field of bioactive lipids. One class of bioactive lipids that have been garnering extensive interest in the past 20 years are the sphingolipids (SL). SLs are lipids that have a sphingosine backbone with a polar head group and nonpolar fatty acid tail. They represent a major class of lipids that have important implications in membrane biology, and as research interest increased and technology advanced, their roles as bioactive lipids have also been extensively studied, elucidating key regulatory functions in organismal development and homeostasis (Sheng, 2018). Unfortunately, SL research has been extremely difficult due to its diversity in structure and the complex regulatory pathways, however, an emerging body of evidence has emphasized the importance of SLs in aging. In this review, we will summarize the SL synthesis pathways and their regulatory elements followed by the contribution of SLs to the hallmarks of aging and age-related diseases. Our goal here is to bring together discoveries from different fields of SL research and to provide a comprehensive view of the evidence for the integral role SL plays in the physiological processes of aging.

**Sphingolipid Biosynthesis Pathway**

Sphingolipids are a vastly diverse class of lipids essential for proper cellular function regulation, particularly structure and signaling. The de novo sphingolipid biosynthesis pathway, through which all sphingolipids are built from nonsphingolipid precursors, begins in the ER (Figure 1A).

First, serine palmitoyltransferase (SPT) catalyzes the condensation of serine and palmitoyl CoA into 3-ketosphinganine followed by reduction into sphinganine by 3-ketosphinganine reductase (Perry, 2002). Next (dihydro)ceramide synthase, commonly known as ceramide synthase (CerS 1-6) converts sphinganine into dihydroceramide (Pewzner-Jung et al., 2006). Based on current evidence, each CerS likely prefers a distinct, but overlapping acyl CoA as a substrate and can form...
different dihydroceramide spices profiles (Riebeling et al., 2003). In final step of the de novo pathway, dihydroceramide is desaturated by dihydroceramide desaturase (DEGS) to form ceramide using molecular oxygen to introduce a hydroxyl group in the C-4 position of dihydroceramide, initiating a NADPH-dependent dehydration reaction forming a double bond in the C4-C5 position (Kraveka et al., 2007). Ceramide can be further hydrolyzed to form sphingosine by ceramidases (CDase) (Figure 1B). Sphingosine is then phosphorylated by sphingosine kinase 1 and 2 (SK1/2) to generate sphingosine-1-phosphate (SIP) (Adams et al., 2020), a pro-survival signaling molecule that acts through 5 G-coupled protein receptors (SIPR 1–5) (Cartier and Hla, 2019). SIP is quickly metabolized by SIP lyase to form hexadecenal and phosphoethanolamine (Zamora-Pineda et al., 2016).

Synthesis of more complex sphingolipids occurs in the Golgi, where glycosylation of ceramide yields complex glycosphingolipids, and phosphate or phosphocholine attachment yields ceramide-1-phosphate (C1P) (Sugiura et al., 2002). The addition of phosphocholine moiety onto the primary hydroxy group of ceramides by sphingomyelin synthase (SMS) forms sphingomyelin (SM) (Figure 1C). SM can also be recycled through the sphingomyelinase enzyme family, which hydrolyzes sphingomyelin’s phosphocholine headgroups to produce ceramide and free phosphocholine (D’Angelo et al., 2018). In mammals, sphingomyelinases can be separated into three main categories based on their optimal pH: acid sphingomyelinase (asmase), alkaline sphingomyelinase (aksmase), and neutral sphingomyelinase (nsmase). Asmase mostly resides in the lysosome (Beckmann et al., 2019) while nsmase is predominantly located on the plasma membrane (Schoenauer et al., 2019). In contrast, aksmase is only expressed in the intestine and liver and aids in the digestion of dietary sphingomyelin (Duan, 2006). Glycosphingolipids are distributed throughout subcellular compartments such as lysosomes and late endosomes where the acidic environment causes the degradation of the oligosaccharides, leading to the formation of ceramide (Kolter and Sandhoff, 2005). Acid ceramidase (ACDases) in the lysosome hydrolyzes ceramide into sphingosine and free fatty acid which leave the lysosome and are recycled back to ceramide (Figure 1D). This step is necessary due to ceramides’ inability to leave the lysosome (Chatelut et al., 1998). This ceramide recycling pathway is known as the salvage pathway and is estimated to be responsible for over half of all sphingolipid biosynthesis (Tettamanti et al., 2003).

**Sphingolipids and Aging**

There is no doubt that SL metabolism plays an integral role in the regulation of almost every biological and physiological processes. Over the past 30 years, SL research has advanced significantly, illuminating and solidifying the importance of SL as a bioactive lipid species that regulates a vast number of biological functions. However, the structural diversity and the complexity of SL metabolism regulation still require a significant amount of research from multiple fields to comprehend the interconnected signaling pathways in addition to the function of each lipid species in a variety of pathological and physiological context. In the following section, we will provide a comprehensive overview of the link between SLs and aging with a particular focus on the major contributions of SLs to the hallmarks of aging and age-related diseases.

**DEREGULATED NUTRIENT SENSING**

As nutrients are required for all biological processes, pathways that govern nutrient sensing are well characterized across many model organisms (Chantranupong et al., 2015). Deregulation of nutrient sensing is also arguably one of the most well studied mechanisms of aging and age-related diseases. Research over the past decade has discovered three major nutrient sensing pathways that play pivotal roles in energy homeostasis. These include AMP kinase (AMPK)/mammalian target of rapamycin (mTOR) and insulin/insulin-like growth factor 1 (IGF-1) signaling (IIS) (Templeman and Murphy, 2018). Recent studies have also linked SL metabolism to each of the these major nutrient sensing pathways and aging (Green et al., 2017).

AMPK signaling is a key component of metabolic energy sensing due to its ability to directly bind to adenosine nucleotides (Crozet et al., 2014). Changes in cellular energy (as measured by changes in the ratio of ATP/ADP and ATP/AMP) activates AMPK, signaling a cascade of downstream signaling pathways including lipid metabolism (Ahmadian et al., 2011), mitochondrial homeostasis (Toyama et al., 2016), glycolysis (Wu et al., 2013) and mTOR signaling (Inoki et al., 2003). AMPK activities have been shown to decrease with the increase of age (Reznick et al., 2007; Ljubicic and Hood, 2009), although the exact mechanisms for the decrease is unknown. Experimental activation of AMPK has been shown to increase lifespan in lower model organisms such as *C. elegans* (Apfeld et al., 2004) and *Drosophila* (Funakoshi et al., 2011). Interestingly, a 2014 study showed that when type 2 diabetics were treated with metformin, a AMPK activator, a 15% mean increase in lifespan was exhibited with matched non-diabetics (Bannister et al., 2014). Currently, the AMPK downstream effector mTOR has allured the attention of researchers worldwide, although there is evidence that suggests possible interactions between AMPK and sphingolipids. One study showed that treatment with myriocin (SPT inhibitor) in yeast extended the lifespan partly through the modulation of the AMPK pathway and protein kinase C downregulation (Liu et al., 2013a). While the SIP agonist drug FTY720 can activate protein phosphatase 2A (PP2A), leading to the dephosphorylation of AMPK at Thr172 and ultimately inducing cell death in multiple myeloma cells (Zhong et al., 2020).

mTOR signaling plays a central role in the sensing of nutrients, including insulin, amino acids and lipids (Um et al., 2004; Tokunaga et al., 2004). Disrupting S6K1, a mediator of mTOR signaling recapitulates metabolic profiles of caloric restriction (Choudhury, 2009), which is one of the most reliable ways of inducing prolonged lifespan in mammals (Madeo et al., 2019). Interestingly, age-related ceramide accumulation, more specifically, C16:0 has been shown to downregulate S6K1 in aging skeletal muscle (Rivas et al., 2012). Furthermore, recent
transcriptomic study revealed that prolonged treatment with C16 ceramide-enriched lipoproteins downregulated several downstream phosphorylated intermediates of mTOR signaling pathway (Hammad, 2020). Moreover, cancer drugs such as doxorubicin, methotrexate and celecoxib increase C16 ceramide levels while reducing cell proliferation (Inoki et al., 2003; Denard et al., 2012; Fekry et al., 2016; Maeng et al., 2017). Overexpression of mammalian ceramide synthase CerS6 in human breast cancer cell line MCF-7 also results in accumulation of C16, leading to deceased cell proliferation due to inhibition of mTOR signaling through the reduction of phosphorylation of AKT, S6K and ERK. Similar inhibition was observed through C16 ceramide treatment as well (Kim et al., 2018). While C16 ceramide confers a negative regulation on mTOR, sphingosine-1-phosphate (SIP) exhibits a positive regulation by increasing mTOR signaling (Kim et al., 2018). This positive regulation has been shown in diverse cell types from primary fibroblasts to cancer cells. SIP interacts with the E3 ubiquitin ligase protein associated with Myc (PAM), which mediates GDP/GTP exchange of Ras homolog enriched in brain (RHEB), and directly activates mTOR signaling independent of ERL, AKT and P13 kinase (Maeurer et al., 2009). This differential regulation of opposing pathways between ceramide and SIP is known as the “SL Rheostat” coined in 1996 after several seminal discoveries demonstrating ceramide’s ability to induce cell growth arrest and apoptosis, while SIP was necessary for optimal cell proliferation and growth as well as the suppression of ceramide mediated growth arrest and apoptosis (Newton et al., 2015).

The insulin/insulin like growth factor signaling pathway (IIS) is perhaps the most promising metabolic pathways mediated by SLs. The IIS pathway is a highly complex metabolic regulatory system which is implicated in aging throughout multiple model organisms from nematodes to vertebrates (Khan et al., 2019). Studies over the last decade have demonstrated the ability of IIS to reconstitute the energy metabolic profile to benefit the short-term physiological needs by forgoing long-term organismal longevity and maintenance (Jøsko et al., 2019). In long lived C. elegans, defense mechanisms against stress conditions such as heat shock, oxidative stress and heavy metals are upregulated through the mediation of the IIS pathway (Lithgow and Walker, 2002) and this finding has been further corroborated in flies (Vermeulen and Loeschke, 2007). Single nucleotide polymorphism studies in humans have suggested a link between the IIS signaling pathway and the determination of human longevity (Deelen et al., 2013), while genetic analysis of human female centenarians has also exhibited an over representation of mutations in insulin like growth factor I (IGF-I) receptor (IGF-IR) associated with reduced IGF-IR activity and increased serum IGF-I (Suh et al., 2008). Interestingly, IGF-IR is localized to membrane microdomains called lipid rafts that are dense in SLs and cholesterol, suggesting that IGF-1 signaling is sensitive to changes in SL metabolism (Hong et al., 2004). Moreover, SIP’s ability to regulate cell fate and modulate energy homeostasis is analogous to that of IIS signaling (Green et al., 2017). IGF-IR activation involves the upregulation of sphingosine kinase and SIP receptor (SIPR) signaling, and the inhibition of either sphingosine kinase activity or the SIPRI and SIPR3 receptors abolished EGF receptor activation potentiated by IGF binding protein 3 (IGFBP-3) in MCF-10A breast epithelial cells (Martin et al., 2009). Evidence suggest that IGFBP-3 is not only able to regulate the availability of IGF, but also exerts direct influence over apoptotic signaling via C2 ceramide mediated apoptosis (Perks et al., 1999). Furthermore, SIP activation of IGF-IR is mediated through its downstream signaling pathway targeting PI3K and Akt (Pyne et al., 2016). Ceramide can also target PI3K and Akt, inhibiting pro-survival signaling through the dephosphorylation of Akt by protein phosphatase (CAPP-PP2A) (Czubowicz and Strosznajder, 2014). Interestingly, ceramide-1-phosphate (C1P) exerts the opposite effect, inhibiting DNA fragmentation, PARP cleavage and caspase stimulation (Gómez-Muñoz, 2005).

Current data suggests extensive involvement of SL metabolism in the regulation of nutrient sensing and aging. The balance between ceramide and sphingosine no doubt contributes to the modulation of the nutrient sensing pathway towards longevity or short-term gains. Although these nutrient sensing pathways have been targets in worms, flies and mice with great success, it is still a topic that requires extensive research. A more comprehensive understanding of SLs is needed before we are able to target these pathways to modulate longevity in humans.

**CELLULAR SENESCENCE**

Cellular senescence is a state of arrested cell proliferation that can be triggered by critical stressors such as DNA damage, telomere shortening, and chromatin disruption. Interestingly, senescence has been shown to be protective and beneficial in the early stages of an organism’s life span (Muñoz-Espin, 2013), contributing to tissue repair and the protection against oncogenic factors. However, in aged organisms, chronic accumulation of senescent cells contributes to the decline of organismal health and age-related diseases (Childs et al., 2014). Recent evidence suggests several contributing factors of age-related accumulation of senescent cells. These include age-associated increase in senescence-inducing stimuli leading to an overall increase in senescent cells (Van Deursen, 2014), age-associated decline of immune function (Solana et al., 2012), and decrease in apoptotic regulation due to age-associated decline in P53 stability (Feng et al., 2007). Senescent cells can also influence neighboring cells in a paracrine manner through a complex secretome of cytokines and other signaling molecules, increasing inflammation and immune cell activation (Franceschi and Campisi, 2014). This phenomenon is referred to as the senescent associated secretory phenotype (SASP) and is the primary culprit in senescent related dysfunctions (Birch and Gil, 2020).

Recent studies have also highlighted the importance of SLs and their role in senescence regulation (Tsayssac et al., 2018). Obeid et al. first noticed a significant increase in ceramide in senescent cells. Furthermore, the addition of exogenous ceramide mirrored several key factors of cellular senescence, including the inhibition of DNA synthesis and cell growth, and dephosphorylation of Retinoblastoma protein (Rb) (Venable et al., 1995). This was
Further recapitulated in human IMR-90 fibroblasts where ceramide level was doubled when comparing senescent to young fibroblast (Meacci et al., 1996). A link between aging tissue and N-SMase activity has also been reported (Jensen et al., 2005) along with a correlation between N-SMase activity and cellular senescence (Venable et al., 1995). However, ceramide may not be the only contributing factor to the induction of senescence. Acid ceramidase (ASAH1) which catalyzes ceramide into fatty acid and sphingosine has also been shown to be highly upregulated in senescent cells, and silencing ASAH1 in presenescent human fibroblasts decreased the expression levels of senescent associated proteins P53, p21, and P16 (Munk et al., 2021). Sphingosine-1-phosphate (S1P), whose role in promoting cellular proliferation and survival has been extensively studied (Proia and Hla, 2015), is generated through the phosphorylation of sphingosine by SK1/2 (Adams et al., 2020). The downregulation of SK1/SK2 or decreased level of cellular S1P has been shown to promote cellular senescence. Furthermore, S1P treatment and the inhibition of CerS reversed the acceleration in senescence, suggesting that the accelerated cellular senescence seen with SK1/2 inhibition was due to the increase in ceramide (Kim et al., 2019). Pharmacological inhibition of SK1/2 induced growth arrest in prostate cancer cells through the modulation of the ceramide synthesis pathway, which enhanced the expression of p53 and p21 (McNaughton et al., 2016). Although the exact mechanisms by which S1P regulates cellular senescence have not been established, evidence suggests that S1P may be an important regulator due to its ability to regulate cellular senescence through the binding of its target receptors. S1P has multiple binding targets, including five G-protein coupled receptors (S1PR1-5), which are responsible for a multitude of cellular functions (Cartier and Hla, 2019). S1PR2 activation induced senescence in endothelial cells that was reversed through S1PR2 shRNA (Lu et al., 2012). Interestingly, S1P can also bind to human telomeres reverse transcriptase (hTERT), mirroring hTERT phosphorylation and stabilizing hTERT and regulating cellular senescence caused by telomere damage (Panneer Selvam et al., 2015). While there is strong evidence highlighting the role of SLs in cellular senescence and aging, the precise mechanisms have yet to be elucidated. However, it would not be overreaching to speculate that the highly regulated intracellular balancing between the pro-survival and pro-apoptotic SLs contributes to the regulation of cellular senescence, and that this complex network comprises of key mediators that interconnect every aspect of cellular function.

**LOSS OF PROTEOSTASIS**

Current understanding of protein homeostasis (proteostasis) and aging is supported by a magnitude of evidence suggesting that a properly functioning proteostasis network is associated with healthy aging, and many molecular interventions have aimed at diminishing the proteotoxic stress of an organism to increase its lifespan (Kaushik and Cuervo, 2015). The most well characterized networks that are responsible for proteostasis are the unfolded protein response (UPR). UPR is compartmentalized into UPR in the ER (UPRER), mitochondrial UPR (UPRmt) and cytosolic UPR (UPRcs) with each compartment possessing a unique framework of genes and proteins differentially regulated during times of stress (Kim et al., 2016). The UPR is responsible for detecting misfolded proteins and restoring it to its proper stable conformation (Kim et al., 2013) or utilizing a proteolytic network that drives the cell towards an autophagic cell fate and eliminates the dysfunctional cell if stress becomes chronic (Pohl and Dikic, 2019). Why our proteostasis network deteriorates as we age is still mostly unknown, however, evidence suggests that upon aging, the chaperone proteins responsible for maintaining proteostasis gradually amass oxidative damage, which lowers their efficiency at reenforcing proper protein refolding (Nuss et al., 2008). Inducibility of the UPR also declines with age in the UPRER as well as UPRmt (Taylor, 2016). Furthermore, overall levels of chaperone proteins have also been shown to decrease with age, resulting in reduced proteostasis regulation and increased proteotoxicity (Taylor and Dillin, 2013).

The classical activators of UPRER are unfolded protein peptides which are recognized by three protein sensors IRE1a, PERK and ATF6a, initiating three separate signaling cascades of the UPRER. However, recent evidence suggests that lipids can also regulate and activate the UPRER. Perturbation of ER membrane lipid composition has been shown to activate UPRER. Furthermore, IRE1a and PERK mutants with their luminal peptide sensing domain removed were able to activate UPRER in mammalian cells, suggesting the presence of a transmembrane lipid sensing domain (Volmer et al., 2013). Halbleib et al. also showed the presence of an amphipathic helix within the transmembrane domain of IRE1. The helices from two IRE1 proteins create transient dimerization configurations, which are stabilized during times of stress due to membrane compression, and upregulate UPRER activity (Halbleib et al., 2017).

The link between lipids and UPR has not been focused on SLs, however, the role of sphingolipids in membrane biology and their ability to manipulate membrane properties have caused an emergence of data. Tam et al. first showed an increase in dihydroceramide and dihydrosphingosine during activation of UPRER. Furthermore, they were able to show that exogenous dihydroceramide and dihydrosphingosine were able to quickly enter the cell, upregulate ATF6, and induce nuclear localization in an array of mammalian cell lines (Tam et al., 2018). During the absence of stress, ATF6 is associated with BiP to inhibit its translocation to the nucleus, however, during times of stress, BiP dissociates from ATF6, allowing for translocation to the nucleus which initiates the UPRER signaling cascade (Susan, 2005). Interestingly, the activation of UPRER through dihydroceramide and dihydrosphingosine did not decrease the association between BiP and ATF6, suggesting that ATF6 exhibits a unique lipid sensing domain in addition to its protein peptide sensing domain that is able to upregulate UPRER (Tam et al., 2018).

The ER is essential to the maintenance of cellular proteostasis through its ability to activate the UPR and to reduce the protein aggregation burden via proteolytic degradation, translational regulation, proteasomal degradation, and autophagy (Hetz, 2012). For example, valosine containing protein (VCP), a...
ubiquitously expressed AAA + atpase removes stalled protein from ER membranes and targets it for proteasomal degradation (Bodnar and Rapport, 2017). Mutations in VCP can lead to a number of developmental defects including inclusion body myopathy, Paget’s disease of the bone, amyotrophic lateral sclerosis and frontotemporal dementia or more commonly known as IBM-PF (Weihl et al., 2009). Interestingly, a lipid enriched diet (LED) was able to rescue the lethal phenotype of homozygous VCP R155H mutant mice as well as to improve disease progression. Furthermore, VCP R155H VCP R155H mutant mice observed increased levels of ceramide, which was decreased to a level closely resembling wild type when put on LED (Llewellyn et al., 2014). SLs has been linked to the disaggregation of polyglutamine (poly-Q) aggregates in C. elegans through the modulation of UPRmit and UPRcyt (Vaena et al., 2021). Reduced expression of the mitochondrial chaperone was able to induce the cytosolic stress response (UPRcyt) and to enhance poly-Q aggregate clearance in C. elegans expressing poly-Q35 repeats. Furthermore, microarray and lipidomic analyses determined that this unique stress response was regulated through lipid metabolism, specifically ceramide and sphingosine (Kim et al., 2016). This regulatory role of ceramide and sphingosine in organisinal stress response and longevity is further supported by the NFTYB-1-SPP-8 axis where perturbation of SL metabolism was able to modulate longevity through alteration of UPRER and UPRmit (Tharyan et al., 2020).

SPHINGOLIPIDS AND OTHER HALLMARKS OF AGING

The link between SLs and aging has become undeniable and the role of SLs in several aspects of aging hallmarks has been extensively studied, however, there are levels of complexity and regulations in other aspects that still require elucidating. Evidence have suggested that very long chain ceramide accumulates during the normal aging process (Cutler et al., 2004). Interestingly, long chain ceramides have been associated with mitochondrial dysfunction, leading to oxidative stress and cell death (Law et al., 2018). A study of mice comparing cardiac mitochondria in aged versus young animals showed that age associated accumulation of mitochondrial ceramide led to a declined mitochondrial function. This decline was reversed by treatment with (R)-α-lipoic acid (LA), a potent anti-oxidant/anti-inflammatory agent which reduced ceramide levels of aged mitochondria to a level comparable with young mitochondria (Monette et al., 2011). Furthermore, it was recently discovered that mitochondrial dysfunction as a result of age-associated ceramide accumulation is induced partly through the inhibition of PKA, leading to the activation of mitochondrial fission factor, dynamin-related protein 1 (Drp1), and ultimately mitophagy (Vaena et al., 2021).

DNA is subjected to damages from a variety of sources daily, which include exogenous factors such as ultraviolet radiation (UV), ionizing radiation (IR), a variety of chemical agents, toxins, and environmental stress, as well as endogenous factors consist of DNA replication error, spontaneous deamination and oxidative DNA damage. In response to the damage, cells utilize the DNA Damage Response (DDR) to mend the damages, thereby preventing prolonged stress and ultimately, cell death. Prolonged DNA damage can lead to genomic instability due to breaks in chromosomal DNA, unwanted mutations and cell death. Genomic instability has been well characterized for its role in cancer development, but its role in aging is still an ongoing research topic. However, there are strong evidence corroborating the notion that genomic instability is a strong driver of aging and age-related disease (Coppede and Migliore, 2012). The link between SLs and DDR was first shown in the early 1990s when increased sphingomyelinase activity and increased ceramide levels were observed in response to DNA damaging agents. The increase in ceramide was able to initiate cell cycle arrest through interactions with other DDR elements (Carroll et al., 2017). DNA damage was further shown to elicit a ceramide accumulation response that was P53 dependent (Dbaibo et al., 1998). This accumulation in ceramide was shown to be partially responsible for promoting cell cycle arrest in response to DNA damage (Phillips et al., 2007). P53 accumulation during DNA damage down regulates SK1, reducing the level of S1P in response to DNA damage. This occurs concomitantly with ceramide accumulation, possibly due to the pro-apoptotic response associated with chronic DNA damage (Taha et al., 2004). Current research has identified several SL metabolites and enzymes that regulate cellular DDR with the potential of offering new therapeutic interventions against DNA damage caused by cancer agents. However, the link between SLs and DDR when pertaining to the aging process requires elucidation.

The role of epigenetic regulation in aging is a topic that has been drawing the attention of researchers since the 1960s (Berdyshev et al., 1967). Chronological age was an imprecise determinant of the aging process, and so the search for biomarkers that could determine biological age began (Baker and Sprott, 1988). The discovery of DNA methylation and how specific CpG methylation sites change throughout aging (Hernandez et al., 2011) has led to the advent of the “Epigenetic Clock”. By utilizing DNA material from blood or tissue, the epigenetic clock estimates the biological age of the specimen through the use of complex mathematic algorithms and advance DNA methylation arrays (Horvath and Raj, 2018). The relationship between the epigenetic regulation of sphingolipids and its impact on the aging process is a topic that has not been well studied, however, recent studies on this topic provides new and exciting insights. Hait et al. showed that nuclear S1P can target histone deacetylase HDAC1 and HDAC2, possibly regulating chromatin state in response to environmental stimulus (Hait et al., 2009). This interaction was further corroborated in mice where the increase in S1P level diminished nuclear HDAC activity, resulting in increase in fatty acid metabolism genes and decrease in inflammation genes (Nguyen-Tran et al., 2014).

Stem cell exhaustion has also been linked to the process of aging although the research density of SLs and their role in stem cell exhaustion is quite low. Non-canonical Wnt signaling is required for the regulation of stem cells essential for development as well as disease (Sugimura and Li, 2010). In the brain, non-canonical Wnt signaling induces stemness of neuronal stem cells.
Very long chain ceramide has been shown to regulate the nonconical Wnt signaling pathway through glycogen synthase kinase 3 (GSK3) (Kong et al., 2015). Incubation with long chain ceramide was able to promote differentiation in human embryonic stem cells (hESC) and induced pluripotent stem cell (iPSC) derived neuroprogenitors (He et al., 2014). Interestingly, S1P has also been shown to mediate hESC self-renewal as well as mouse embryonic stem cell differentiation (Rodgers et al., 2009).

As the lipid landscape changes throughout the aging process, altered intercellular communication occurs as a product of several aberrant physiological processes involving SLs. As mentioned above, lipid rafts are micro domains primarily constructed of SLs and cholesterol. They serve as signaling hubs for a diverse range of cellular processes including proliferation, migration and survival (Mollinedo and Gajate, 2015). However, age-related change in SL levels disrupts the microdomain, leading to altered cellular signaling, resulting in neuropathologies (Mesa-Herrera et al., 2019). Age related increase in senescent cells contributes to altered intercellular communication through the senescence-associated secretory phenotype (SASP). Senescent cells can trigger neighboring cells to enter senescence through gap junction mediated cell to cell contact, propagating senescence to nearby cells (Nelson et al., 2012). The SASP results in an imbalance of cytokine expression and altering cellular communication towards a pro-inflammation state. This phenomenon is known as “inflamming” and is described in extensive detail by Rea et al (2018).

**SPHINGOLIPIDS AND AGE-RELATED DISEASES**

**Neurodegenerative Diseases**

The complex proteostasis network responsible for managing misfolded proteins is subjected to extensive regulations, however, as we age, our proteostasis network begins to deteriorate due to the accumulation of oxidative damage and overall decrease in chaperone levels, causing increased protein aggregation stress on the cell and leading to disease states (Martinez et al., 2017). A deteriorating UPR could lead to the accumulation of neurotoxic aggregates associated with neurodegenerative diseases. Protein aggregation is considered a defining characteristic in multiple neurodegenerative disease which includes Amyloid Beta (Aβ) and Hyperphosphorylated tau (Tau) in Alzheimer’s Disease (AD), Alpha-synuclein (a-syn) in Parkinson’s Disease (PD) and poly-glutamine (poly-Q) in Huntington’s Disease (HD). Although the protein aggregate associated with each of the disease is different, aging is a common risk factor that is shared among them (Kurtishi et al., 2019). When the protein aggregate burden begins to outpace the proteostasis network, neurotoxic proteins can accumulate, leading to disease-associated protein aggregation (Tanaka and Matsuda, 2014). In the past decade, research has suggested regulatory roles of SL in neuronal cell growth, differentiation, survival and apoptosis (Hirabayashi and Furuya, 2008). Due to the SL-rich composition of the brain as well as the complex involvement of SL in brain physiology, it comes as no surprise that aberrant SL metabolism is linked to neurodegenerative diseases (Haughey, 2010). Due to the interconnectivity of the SL metabolism, changes in a single node of the metabolic pathway could lead to dramatic changes in subsequent metabolic intermediates. The sphingolipid rheostat was established to encapsulate the differential regulation of cellular fitness (Cuvillier et al., 1996). Interestingly, age-related disease exhibits a similar theme of SL alterations, displaying an inverse balance between pro-survival and pro-death SL signaling (Figure 2A). The following section will summarize several key involvements of SLs in AD, PD and HD.

**Alzheimer’s Disease**

In AD, SL metabolism has been shown to be perturbed in patients even before the manifestation of clinical symptoms, and tipping the balance of SLs to favor ceramide contributes to the overall disease progression of AD (Varma et al., 2018). SLs, along with cholesterol, form a lipid rich microdomain called lipid rafts which house many signaling molecules and have been associated with aging and neurodegeneration (Ohno-Iwashita et al., 2010). Interestingly, amyloid precursor protein (APP), along with several key enzymes responsible for the cleavage of APP, including BACE-1, have all been shown to co-localize to lipid rafts (Hicks et al., 2012). The disruption of lipid raft through cholesterol depletion showed an inhibition in the formation of Aβ (Simons et al., 1998). SL deficiency has also been shown to alter APP cleavage, possibly through the alteration of lipid raft structure interfering with function (Sawamura et al., 2004). However, ceramide was shown to increase beta APP cleavage through the stabilization of BACE-1, leading to increased Aβ production (Puglielli et al., 2003). The main genetic determinant of AD is the polymorphic alleles of ApoE, a cholesterol carrier whose implication in AD has been extensively studied (Liu et al., 2013b). Kurano et al. have shown that ApoE accelerates the clearance of circulating S1P and ApoM (Kurano et al., 2015), which further emphasize the importance of SLs in AD and aging.

Ceramide accumulation is associated with early stages of AD while an overall decrease in ceramide levels is observed in late stage AD (Katsel et al., 2007). An increase in ceramide levels in early stages of AD sensitizes neuronal cells to pro-death regulation (Jana1 et al., 2009). Furthermore, this increase in ceramide is a direct result of CerS activation, which increases de novo ceramide synthesis, particularly of the C22:0 and C24:0 species (Katsel et al., 2007). Interestingly, Aβ has also been shown to mediate the increase in SPT activity, resulting in increased de novo synthesis of ceramide. The inhibition of SPT in mice resulted in decreased SPT and ceramide levels along with a decline in Aβ and hyperphosphorylated tau (Hirosa Geekiyanagea et al., 2013). Although the de novo pathway is responsible for the early increase in ceramide levels, the main source of ceramide in AD originates from the hydrolysis of sphingomyelin as a result of Aβ ( ). In postmortem AD patients, analysis of senile plaques showed increased levels of ceramide saturation and nsmase/asmase (Panchal, 2014). Aβ induces neuronal apoptosis through the upregulation of ceramide by nsmase and asmase (Malaplate-Armand, 2006).
Although the implications of the accelerated S1P clearance in AD requires elucidation, one can speculate that the decreasing plasma levels of S1P over the course of aging could possibly tip the balance of SL regulation towards pro-death. This, along with the Aβ mediated increase in ceramide levels could result in a cascade of ceramide mediated neuronal cell death and exacerbate the AD phenotype.

Parkinson’s Disease

One of the defining characteristics of PD is the presence of Lewy Bodies (LB) which are fibrillar aggregates mainly composed of α-syn (Wakabayashi et al., 2007). Deletion of the gene coding for α-syn (SNCA) has been linked to altered SL metabolism (Golovko, 2005) and dysfunction in SL metabolism has been associated with the presence of Lewy bodies (Rocha, 2015). Recent evidence suggests aberrant endolysosomal pathways play a key role in the development of PD. Due to the importance of membrane dynamics in proper lysosomal function, altered SLs may contribute to lysosomal dysfunction and the exacerbation of PD (Song et al., 2016). The autophagy-lysosome pathway is responsible for the removal of toxic protein aggregates such as α-syn. Impaired function could lead to the accumulation of neurotoxic aggregates, leading to PD state (Pan et al., 2008). Mutation in PLA2G6, a phospholipase gene associated with PD and PD-like disease onset resulted in neurotoxicity due to increased levels of ceramide via increased ceramide recycling. Reduction in ceramide through phenological or genetic manipulation resolved PLA2G6 neurotoxic phenotype in flies (Lin, 2018). This was further corroborated in PD associated VPS35 gene variant where improved fitness was achieved through ceramide manipulation (Lin, 2018). Gaucher Disease (GD) is a lysosome storage disease (LSD) caused by biallelic mutation in the GBA (acid beta-glucocerebroside) gene, which encodes a SL metabolism enzyme. Patients with a heterozygous recessive variants of GBA have significantly increased risk of PD (Sidransky et al., 2010). Furthermore, loss of function mutation in GBA inhibited the autophagy-lysosome pathway, resulting in increased α-syn levels (Du et al., 2015). Brain specimens taken from GD patients exhibited α-syn positive lewy bodies (Wong, 2004), while a loss of GBA in human pluripotent-stem-cell derived dopamine neurons led to neuronal death due to α-syn accumulation induced lysosome dysfunction (Mazzulli, 2011). The role of S1P has also been explored in PD. pharmacological inhibition of SK1 reduced survival of dopaminergic neurons in a PD mouse model while exogenous S1P exhibited neuroprotective effects through the inhibition of apoptosis (Pyszko and Strosznajder, 2014).

Huntington’s Disease

HD is a genetic neurodegenerative disease that is autosomal dominant and presents with a wide range of physical, behavioral and cognitive defects (Vonsattel and DiFiglia, 1998). Similar to other neurodegenerative disease, alterations in SL metabolism can be detected early on in the HD pathology (Pardo et al., 2017). Recent studies have suggested a link between altered SL metabolism and HD pathology. S1P levels in HD mouse models exhibited upregulation of S1P lyase (SGPL1) as well as a downregulation in SphK1. This was further corroborated in human striatal and cortical specimens
from human HD patients (Pardo, 2017). Treatment with K6PC-5 (SphK1 activator) in HD mouse model resulted in increased S1P levels and improved intestinal cell integrity and prevented body weight loss (Pardo, 2020). K6PC-5 treatment also further prevented motor defects in R6/2 HD mice model as well as reduced mutant huntingtin aggregations. This was accomplished through the activation of pro-survival signaling and increased autophagy (Di Pardo, 2019). S1P manipulation through drug targeting has shown positive results in improving HD pathology. FTY720 treatment of R6/2 mice showed improved lifespan and motor function along with reduced brain atrophy. Furthermore, FTY720 treatment reduced the levels of cytotoxic signaling molecules that would otherwise lead to neurotoxic astrocyte activation (Pardo et al., 2014; Miguez et al., 2015). A-971432 (S1PR5 Agonist) treatment of R6/2 HD mice significantly improved lifespan. Additionally, when A-971432 treatment was administered early, prior to the onset of disease symptoms, it protected the mice from HD associated progressive neuromotor defects (Pardo et al., 2018). Although research in the relationship between SLs and HD is scattered, there is promising evidence suggesting that the targeting of the S1P axis will improve HD pathology and disease management.

Cancer

One of the biggest risk factors for cancer is old age (Niccoli and Partridge, 2012). It is no coincidence that the hallmarks of aging strikingly resembles the hallmarks of cancer (Hanahan and Weinberg, 2011). Aging confers genomic instability due to the accumulation of DNA mutations which ultimately grants a gain-of-function mutation, allowing the cell to proliferate uncontrollably, migrate and survive the immune system (Hanahan and Weinberg, 2011). While some cells proliferate due to gain-of-function mutations, others enter a senescent state, preventing them from propagating their DNA damage (Coppé et al., 2010). Along with mutation accumulation, telomere shortening due to continued replication throughout aging induces senescence as well (Bernadotte et al., 2016). It comes as no surprise that senescent cell numbers also increase with age, however, increase cellular senescence is a potent driver of hyperplasia (Robert et al., 2020).

Recent evidence has suggested that the modulation of SLs also contributes significantly to cancer pathology (Sheng, 2018). S1P has been shown to exert pro-survival effects on cancer cells, promoting proliferation, migration, transformation and inhibiting ceramide induced apoptosis (Cuvillier et al., 1996), while ceramide confers sensitivity to chemotherapeutic drugs, senescence, cancer cell apoptosis and growth arrest (Morad and Cabot, 2013). Recent studies have solidified the role of Sphingosine kinase 1 (SK1) in cancer (Heffernan-Striud and Obeid, 2013). This is best documented in human colon cancer where 89% of cases exhibit upregulation in SK1 (S1P knockdown mice exhibited inhibitory effects in colon tumor development as well as increased apoptotic colon cancer cells (Kawamori, 2009). Along with the increase in S1P through SK1, S1P lyase downregulation in colon cancer has also been documented, further increasing pro-survival S1P signaling (Oskouian, 2006). Many of the current chemotherapeutic drugs have been shown to increase ceramide generation through several key synthesis pathways. Increased cellular S1P through the siRNA inhibition of S1P phosphatase one in MCF-7 cells conferred resistance to chemotherapeutic agent daunorubicin (Johnson, 2003). Other chemotherapeutic agents such as Gemcitabine (Chalfant, 2002) and doxorubicin (Lépine et al., 2011) increased ceramide levels through the de novo pathway which can be partially inhibited with treatment of myricin, an inhibitor of SPT. Daunorubicin upregulates ceramide synthase activity, resulting in increased de novo ceramide synthesis (Bose, 1995). Cytosine arabinoside increases ceramide levels through the activation of N-SMase by generating reactive oxygen species (Bezombes, 2001). The reduced level of ceramide in cancer cells drives the cells towards a pro-survival phenotype. This can be further validated in the upregulation of acid ceramidase (acdase) enzyme in several cancer types, which is responsible for the degradation of ceramide into sphingosine (Mahdy, 2009; Bizzozero, 2014). Inhibition of acdase combined with chemotherapeutic drugs has shown promise in inducing cancer cell death (Realini, 2016).

Therapy Targeting Sphingolipids

The multilayered regulatory synthesis pathway of sphingolipid metabolism provides many opportunities for pharmacological intervention. However, most sphingolipid therapies revolve around age-related disease, and little is known about its effects on aging. The forerunner of sphingolipid therapy is a S1PR modulating drug called FTY720, which is currently FDA-approved for the treatment of relapsing remitting forms of multiple sclerosis (MS) (Brinkmann, 2002). FTY720 has also been heavily researched as an anti-cancer therapeutic in a multitude of organ systems including leukemia (Neviani, 2007), glioblastoma (Estrada-Bernal et al., 2012), breast cancer (Azuma, 2002), non-small cell lung cancer (Booth et al., 2019), pancreatic cancer (Lankadasari, 2018) and mesothelioma (Szymiczek, 2017). Targeting the SphK-S1P-S1PR pathway has been a promising anti-cancer strategy that has given rise to many other candidates. For example, SK1-I and PF-543, two potent SphK1 inhibitors, suppress the growth of glioblastoma (Kapitonov, 2010) and colorectal cancer cells (Ju et al., 2016) in xenograft mouse model, respectively. Other drugs targeting S1PR1/3 (VPC03090) (Kennedy, 2011) and S1PR2 (AB1) (Li et al., 2015) are also under further evaluation to be possible future anti-cancer drugs. Currently, there are five drugs that reproducibly extend lifespan in mice: rapamycin, acarbose, nordihydroguaiaretic acid, 17-alpha-oestradiol and aspirin (Nadon et al., 2017). Of the five, rapamycin presents an interesting topic for future sphingolipid research due to mTORC being the target for its mechanism of action (Schreiber, 2019). Identifying the change in sphingolipid landscape under the influence of rapamycin induced lifespan extension could provide a more coherent view of how sphingolipids regulate lifespan, as well as provide insight for the development of new pharmacological interventions. One interesting field of research that is currently ongoing is the use of sphingolipids as a biomarker for aging. Serum sphingolipids have been proposed to serve as biomarkers of obesity (Mu, 2013) and AD (Mielke and Haughey, 2012). While serum C16 shows
promise as a biomarker for gait speed, a robust measurement for physical functional decline (Wennberg, 2018). The usefulness of sphingolipid as a biomarker is further supported by lipidomic data from centenarians (Montoliu, 2014), solidifying the need for further exploration to identify the relationship between sphingolipid metabolism and the aging process.

CONCLUSION

The impact of SLs can be observed in almost every field of aging research. In this review, we provided a complete summary of sphingolipids and their role in the hallmarks of aging (Figure 2B). However, the complexity in their diversity and regulation is reflected in the fragmented data in their roles in age regulation. Although recent evidence due suggest that targeting the SL metabolism pathway alters lifespan, the underlying molecular pathways need further elucidating.

Furthermore, the biochemical and molecular mechanisms that govern the regulation of enzymes involved in the SL metabolism pathway, as well as the mechanistic action of the many species of SL intermediates requires further unraveling. Due to the interconnectedness of SLs, a comprehensive understanding of SL structure, subcellular localization and the regulation of its enzymes and pathway will be required for safe and effective modulation of the aging process, in addition to enabling the development of precise and effective therapeutic tools in the fight against age-related diseases. Although the hallmarks represent a foundation in which aging can be systematically defined, it is by no means a complete picture of the aging process. Science is still far from fully understanding the aging process, and the challenges of studying aging and longevity in humans have proven extremely difficult. In mice, therapeutic targets aimed at several hallmarks of aging can increase lifespan by 15–20%, however, this comes at a cost of decreased fitness and physiological defects. This cost for longevity would explain the absence of long-lived phenotypes in humans due to the importance of survival fitness. Ongoing research into centenarians has shed some light into the aging process, characterizing lipid profiles and genetic contributing factors of centenarians and their offspring compared to the average human. As scientists slowly unravel the intricacies of aging, the interconnected network of SL metabolism and its implications in aging is going to be an exciting and dynamic field for future research.

AUTHOR CONTRIBUTIONS

SL and H-EK wrote and edited the manuscript. SL made all the figures.

FUNDING

This work is supported by the University of Texas System-Rising Stars Award: 26532, University of Texas Health Science Center at Houston: 37516.

ACKNOWLEDGMENTS

We thank Nan Xin for critically reading this manuscript and providing comments. We thank Emily Ma for helping with organizing the references.

REFERENCES

Adams, D. R., Pyne, S., and Pyne, N. J. (2020). Structure-function Analysis of Lipid Substrates and Inhibitors of Sphingosine Kinases. Cell Signal. 76, 109806. doi:10.1016/j.cellsig.2020.109806

Ahmadian, M., Abbott, M. J., Tang, T., Hudak, C. S. S., Kim, Y., Bruss, M., et al. (2011). Desnutrin/ATGL Is Regulated by AMPK and Is Required for a Brown Adipose Phenotype. Cell Metab. 13, 739–748. doi:10.1016/j.cmet.2011.05.002

Apfeld, J., O'Connor, G., McDonagh, T., DiStefano, P. S., and Curtis, R. (2004). The AMP-Activated Protein Kinase AAK-2 Links Energy Levels and Insulin-like Signals to Lifespan in C. elegans. Genes Dev. 18, 3004–3009. doi:10.1101/gad.1255404

Azuma, H. (2002). Marked Prevention of Tumor Growth and Metastasis by a Novel Immunosuppressive Agent, FTY720, in Mouse Breast Cancer Models. Cancer Res. 62, 1410–1419.

Baker, G. T., and Sprott, R. L. (1988). Biomarkers of Aging. Exp. Gerontol. 23, 223–239. doi:10.1016/0531-5565(88)90025-3

Bannister, C. A., Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Scherthanharner, G., et al. (2014). Can People with Type 2 Diabetes Live Longer Than Those without? A Comparison of Mortality in People Initiated with Metformin or Sulphonylurea Monotherapy and Matched, Non-diabetic Controls. Diabetes Obes. Metab. 16, 1165–1173. doi:10.1111/dom.12354

Beckmann, N., Becker, K. A., Kadow, S., Schumacher, F., Kramer, M., Kuhn, C., et al. (2019). Acid Sphingomyelinase Deficiency Ameliorates farber Disease. Ijms 20, 6253. doi:10.3390/ijms20246253

Berdyshov, G. D., Korotaev, G. K., Boiarstkikh, G. V., and Vanishunsh, B. F. (1967). [Nucleotide Composition of DNA and RNA from Somatic Tissues of Humpback and its Changes During Spawning]. Biokhimia 32, 988–993.

Bernadotte, A., Mikhelson, V. M., and Spivak, I. M. (2016). Markers of Cellular Senescence. Telomere Shortening as a Marker of Cellular Senescence. Aging (Albany, NY) 8, 3–11. doi:10.18632/aging.100871

Bezombes, C. (2001). Oxidative Stress-induced Activation of Lyn Recruits Sphingomyelinase and Is Requisite for Its Stimulation by Ara-C. FASEB J. 15, 1583–1585. doi:10.1096/fj.00-07875p

Birch, J., and Gil, J. (2020). Senescence and the SASP: Many Therapeutic Avenues. Genes Dev. 34, 1565–1576. doi:10.1101/gad.343129.120

Bizzozero, L. (2014). Acid Sphingomyelinase Determines Melanoma Progression and Metastatic Behaviour via the Microphthalmia-Associated Transcription Factor Signalling Pathway. Cell Death Differ. 21, 507–520. doi:10.1038/cdd.2013.173

Bodnar, N., and Rapoport, T. (2017). Toward an Understanding of the Cd48/p97 ATPase. F1000Res 6, 1318–1410. doi:10.12688/f1000research.11683.1

Booth, L., Roberts, J. L., Spiegel, S., Poklepovic, A., and Dent, P. (2019). Fingolimod Augments Pemetrexed Killing of Non-small Cell Lung Cancer and Overcomes Resistance to ERBB Inhibition. Cancer Biol. Ther. 20, 597–607. doi:10.1080/15384047.2018.1538616

Bose, R. (1995). Ceramide Synthase Mediates Daunorubicin-induced Apoptosis: An Alternative Mechanism for Generating Death Signals. Cell 82, 405–414. doi:10.1016/0092-8674(95)90429-8

Brinkmann, V. (2002). The Immune Modulator FTY720 Targets Sphingosine 1-phosphate Receptors. J. Biol. Chem. 277, 21453–21457. doi:10.1074/jbc.C200176200
Bustos, V., and Partridge, L. (2017). Good OL Fat: Links between Lipid Signaling and Longevity. Trends Biochem. Sci. 42, 812–823. doi:10.1016/j.tibs.2017.07.001

Carroll, B., Donaldson, C., and Obeid, L. (2017). Sphingolipids in the DNA Damage Response. Physiol. Behav. 176, 139–148.

Cartier, A., and Hla, T. (2019). Sphingosine 1-phosphate: Lipid Signaling in Pathology and Therapy. Science 366. doi:10.1126/science.aar5551

Chalfant, C. E. (2002). De Novo ceramide Regulates the Alternative Splicing of De Bouard, B., Lee, C., and Ye, J. (2012). Doxorubicin Blocks Proliferation of Cancer Cells through Proteolytic Activation of CREB3L1.

Chatelut, M., Leruth, M., Harzer, K., Dagan, A., Marchesini, S., Gatt, S., et al. (2012). Induction of Brain Tumor Stem Cell Apoptosis by FTY720: A Potential Therapeutic Agent for Glioblastoma. Neuro. Oncol. 14, 405–415. doi:10.1093/neuonc/nos005

Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R. H., Shimizu, T., et al. (2009). Update of the LIPI9D MAPS Comprehensive Classification System for Lipids. J. Lipid Res. 50, 59–514. doi:10.1194/jlr.R800095-1ER20

Fekry, R., Esmailnia, V, Khashabi, A., Krupenko, S. A., and Krupenko, N. I. (2016). Ceramide Synthase 6 Is a Novel Target of Metabolite Mediation through Its Antiproliferative Effect in a P53-dependent Manner. PLOS One 11, e0146618–17. doi:10.1371/journal.pone.0146618

Feng, Z., Hu, W., Teresky, A. K., Hernandez, E., Cordon-Cardo, C., and Levine, A. J. (2007). Declining P53 Function in the Aging Process: A Possible Mechanism for the Increased Tumor Incidence in Older Populations. Proc. Natl. Acad. Sci. 104, 16633–16638. doi:10.1073/pnas.0708043104

Franceschi, C., and Campisi, J. (2014). Chronic Inflammation (Inflammaging) and its Potential Contribution to Age-Associated Diseases. Journals Gerontol. Ser. A: Biol. Sci. Med. Sci. 69, S4–S8. doi:10.1097/gerona glut5759

Funakoshi, M., Tsuda, M., Muramatsu, K., Hutsuda, H., Morishita, S., and Aigaki, T. (2011). A Gain-Of-Function Screen Identifies Wbdl and Lkb1 as Lifespan-Extending Genes in Drosophila. Biochim. Biophys. Res. Commun. 405, 667–672. doi:10.1016/j.bbrc.2011.01.090

Golovko, M. Y. (2005). A-Synuclein Gene Deletion Decreases Brain Palmitate Uptake and Alters the Palmitate Metabolism in the Absence of A-Synuclein Palmitate Binding. Biochemistry 44, 8251–8259. doi:10.1021/bi0502137

Gómez-Muñoz, A. (2005). Ceramide-1-phosphate Promotes Cell Survival through Activation of the Phosphatidylinositol-3 kinase/protein Kinase B Pathway. Rev. EBS Lett. 579, 3744–3750.

Green, C., Mitchell, S., and Speakman, J. (2017). Energy Balance and the Sphingosine-1-Phosphate/Ceramide Axis. Aging 9, 2463–2464. doi:10.1086/671034

Grimm, M. O. W. (2005). Regulation of Cholesterol and Sphingomyelin Metabolism by Amyloid-ß and Presenilin. Nat. Cell Biol. 7, 1118–1123. doi:10.1038/nch1313

Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., et al. (2009). Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate. Science 325, 1254–1257. doi:10.1126/science.1176799

Hillbell, K., Pesek, K., Covino, R., Hofbauer, H. F., Wunnicke, D., Hänelt, I., et al. (2017). Activation of the Unfolded Protein Response by Lipid Bilayer Stress. Mol. Cell 67, 6738–684. doi:10.1016/j.molcel.2017.06.012

Hammad, S. M. (2020). Transcriptomics Reveal Altered Metabolic and Signaling Pathways in Podocytes Exposed to C16. Genes (Basel) 11, 178. doi:10.3390/genes11020178

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell 144, 646–674. doi:10.1016/j.cell.2011.02.013

Haughey, N. J. (2010). Sphingolipids in Neurodegeneration. Neuron. Mol. 12, 301–305. doi:10.1016/j.neuron.2010.10-8135

He, Q., Wang, G., Wakade, S., Dasgupta, S., Dinkins, M., Kong, J. N., et al. (2014). Primary Cilia in Stem Cells and Neural Progenitors Are Regulated by Neutral Sphingomyelinase 2 and Ceramide. MBoC 25, 1715–1729. doi:10.1093/mboce/mot052

Heffner-Struid, L., and Obeid, L. M. (2013). Sphingosine Kinase 1 in Cancer. Adv. Cancer Res. 117, 201–235.

Hernandez, D. G., Nalls, M. A., Gibbs, J. R., Arepalli, S., van der Brug, M., Chong, S., et al. (2011). Distinct DNA Methylation Changes Highly Correlated with Chronological Age in the Human Brain. Hum. Mol. Genet. 20, 1164–1172. doi:10.1093/hmg/ddq61

Hetz, C. (2012). The Unfolded Protein Response: Controlling Cell Fate Decisions under ER Stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102. doi:10.1038/nrm3270

Hicks, D. A., Nalivava, N. N., and Turner, A. J. (2012). Lipid Rafs and Alzheimer’s Disease: Protein-Lipid Interactions and Perturbation of Signaling. Front. Physiol. 3 (JUN), 189–218. doi:10.3389/fphys.2012.00189

Hirabayashi, Y., and Furuya, S. (2008). Roles of L-Serine and Sphingolipid Metabolism in Brain Development and Neuronal Survival. Prog. Lipid Res. 47, 125–145. doi:10.1016/j.plipres.2008.01.003

Hirota Geekiyana, E., Upadhye, Aditi, and Chan, C. (2013). Inhibition of SPT Reduces Aβ and Tau Hyperphosphorylation in a Mouse Model, a Safe Therapeutic Strategy for Alzheimer’s Disease. Neurobiol. Aging 34, 2037–2051. doi:10.1016/j.neurobiolaging.2013.02.001

Hong, S., Huo, H., Xu, J., and Liao, K. (2004). Insulin-like Growth Factor-1 Receptor Signaling in SY33-L1 Adipocyte Differentiation Requires Lipid Rafts but Not Caveolae. Cell Death Differ. 11, 714–723. doi:10.1038/sj.cdd.4401405
Horvath, S., and Raj, K. (2018). DNA Methylation-Based Biomarkers and the Epigenetic Clock Theory of Ageing. *Nat. Rev. Genet.* 19, 371–384. doi:10.1038/s41576-018-0004-3

Inoki, K., Zhu, T., and Guan, K.-L. (2003). TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival. *Cell* 115, 577–590. doi:10.1016/S0092-8674(03)00929-2

Janaí, A., Hogaz, E. L., and Pahan, K. (2009). Ceramide and Neurodegeneration: Susceptibility of Neurons and Oligodendrocytes to Cell Damage and Death. *Arthritis Res. Ther.* 11, 5–15. doi:10.1186/ar2540

Kennedy, P. C. (2011). Characterization of a Sphingosine 1-phosphate Receptor Activator Prodrug. *Drug. Sci. Ther.* 338, 879–889. doi:10.1124/jpet.111.181552

Kapitonov, D. (2010). Targeting Sphingosine Kinase 1 Inhibits AKT Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts. *Cancer Res.* 69, 6915–6923. doi:10.1158/0008-5472.CAN-09-0664

Katsel, P., Li, C., and Haroutunian, V. (2007). Gene Expression Alterations in the Susceptibility of Neurons and Oligodendrocytes to Cell Damage and Death. *J. Neurol. Sci.* 250, 5–15. doi:10.1016/j.jns.2008.12.010

Kurano, M., Tsukamoto, K., Hara, M., Ohkawa, R., Ikeda, H., and Yatomi, Y. (2015). LDL Receptor and ApoE Are Involved in the Clearance of ApoM-Associated Sphingosine 1-phosphate. *J. Biol. Chem.* 290, 2477–2488. doi:10.1074/jbc.m114.596445

Lépine, S., Allegood, J. C., Edmonds, Y., Målstén, S., and Spiegel, S. (2011). Autophagy Induced by Deficiency of Sphingosine-1-Phosphate Phosphohydrolase 1 Is Switched to Apoptosis by Calpain-Mediated Autophagy-Related Gene 5 (Atg5) Cleavage. *J. Biol. Chem.* 286, 24360–243610. doi:10.1074/jbc.M110.116106

Lin, G. (2018). Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain. *Cell Metab.* 28, 605–618. doi:10.1016/j.cmet.2018.05.019

Lithgow, G. J., and Walker, G. A. (2002). Stress Resistance as a Determinate of C. elegans Lifespan. *Mech. Ageing Development* 123, 765–771. doi:10.1016/S0047-2484(02)00422-5

Liu, C.-C., Kanekiyo, T., Xu, H., Bu, G., and Bu, G. (2013). Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy. *Nat. Rev. Neuroil.* 9, 106–118. doi:10.1038/nrneurol.2012.263

Liu, J., Huang, X., Withers, B. R., Blalock, E., Liu, K., and Dickson, R. C. (2013). Reducing Sphingolipid Synthesis Orchestrates Global Changes to Extend Yeast Lifespan. *Aging Cell* 12, 833–841. doi:10.1111/agec.12107

Ljubivich, V., and Hood, D. A. (2009). Diminished Contraction-Induced Intracellular Signaling towards Mitochondrial Biogenesis in Aged Skeletal Muscle. *Aging Cell* 8, 394–404. doi:10.1111/j.1474-9726.2009.00483.x

Lujewski, J. N., Balbánek, A., Jung, K.-M., Nguyen, C., Avenas, A., Mozáfi, T., et al. (2014). Lipid-enriched Diet Rescues Lethality and Slows Down Progression in a Murine Model of VCP-Associated Disease. *Hum. Mol. Genet.* 23, 1333–1344. doi:10.1093/hmg/ddt523

López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of Aging. *Cell* 153, 1194–1217. doi:10.1016/j.cell.2013.05.039

Luo, H., Yuan, H., Chen, S., Huang, L., Xiang, H., Yang, G., et al. (2012). Senescent Endothelial Dysfunction Is Attributed to the Up-Regulation of Sphingosine-1-Phosphate Receptor-2 in Aged Rats. *Mol. Cell. Biochem.* 363, 217–224. doi:10.1007/s11010-011-1173-y

Madero, F., Carmona-Gutierrez, D., Hofer, S. J., and Kroemer, G. (2019). Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential. *Cell Metab.* 29, 592–610. doi:10.1016/j.cmet.2019.01.018

Mahd, H., Song, J.-H., Kim, G.-T., Song, Y.-J., Lee, K., Kim, J.-Y., et al. (2017). Oleo Coxib-mediated Activation of Endoplastic Reticulum Stress Induces New Ceramide Biosynthesis and Apoptosis in Hepatoma HepG2 Cells. *BBM Rep.* 30, 144–149. doi:10.5483/bbrm.2017.50.3.197

Maeurer, C., Holland, S., Pierre, S., Potstadà, W., and Scholich, K. (2009). Sphingosine-1-phosphate Induced mTOR-Acivation Is Mediated by the E3 Ubiquitin Ligase PAM. *Cell Signal.* 21, 293–300. doi:10.1016/j.cellsig.2008.10.016

Madjy, A. M. (2009). Acid Ceramidease Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer. *Mol. Ther.* 17, 430–438. doi:10.1038/mt.2008.281
Malaplate-Armand, C. (2006). Soluble Oligomers of Amyloid-β Peptide Induce Neuronal Apoptosis by Activating a cPLA2-dependent Sphingomyelinase-Ceramide Pathway. *Neurobiol. Dis.*, 23, 178–189. doi:10.1016/j.nbd.2006.02.010

Martin, J. L., Lin, M. Z., McGowan, E. M., and Baxter, R. C. (2009). Potentiation of Growth Factor Signaling by Insulin-like Growth Factor-Binding Protein-3 in Breast Epithelial Cells Requires Sphingosine Kinase Activity. *J. Biol. Chem.*, 284, 25542–25552. doi:10.1074/jbc.M109.077120

Martinez, G., Duran-Aniotz, C., Cabral-Miranda, F., Vivar, J. P., and Hetz, C. (2017). Endoplasmic Reticulum Proteostasis Impairment in Aging. *Aging Cell* 16, 615–623. doi:10.1111/acel.12599

Mazzulli, J. R. (2011). Gaucher Disease Glucosylceroidosidase and α-synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. *Cell* 146, 37–52. doi:10.1016/j.cell.2011.06.001

McNaughton, M., Pitman, M., Pitson, S. M., Pyne, N. J., and Pyne, S. (2016). Proteasomal Degradation of Sphingosine Kinase 1 and Inhibition of Dihydroceramide Desaturase by the Sphingosine Kinase Inhibitors, SKI or SKII. *Int. J. Cell Biol.* 2016, 6765. doi:10.1186/1539-7607-2016-6755

Morad, S. A. F., and Cabot, M. C. (2013). Ceramide-orchestrated Signalling in Prostate Cancer Cells. *Oncotarget* 4, 2017–2027. doi:10.18632/oncotarget.1094.

Nadon, N. L., Strong, R., Miller, R. A., and Harrison, D. E. (2017). NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model. *N Engl. J. Med.* 377, 525–536. doi:10.1056/nejmct1700171

Neviani, P. (2007). FTY720, a New Alternative for Treating Blast Crisis Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia. *J. Clin. Invest.* 117, 2408–2421. doi:10.1172/jci31095

Newton, J., Lima, J., Maceyka, M., and Spiegel, S. (2015). Revisiting the Sphingolipid Rheostat: Evolving Concepts in Cancer Therapy. *Exp. Cell Res.* 333, 195–200. doi:10.1016/j.yexcr.2015.02.025

Nguyen-Tran, D. H., Hait, N. C., Sperber, H., Qi, J., Fischer, K., Ieronimakis, N., et al. (2014). Molecular Mechanism of Sphingosine-1-Phosphate Action in Dichelous Muscular Dystrophy. *Dis. Model. Mech.* 7, 41–54. doi:10.1242/dmm.013631

Niccoli, T., and Partridge, L. (2012). Aging as a Risk Factor for Disease. *Curr. Biol.* 22, R741–R752. doi:10.1016/j.cub.2012.07.024

Nishizuka, Y. (1992). Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C. *Science* 258, 607–614. doi:10.1126/science.1411571

Nuss, J. E., Choksi, K. B., DeFord, J. H., and Papaconstantinou, J. (2008). Decreased Enzyme Activities of Chaperones PD1 and BiP in Aged Mouse Livers. *Biochem. Biophys. Res. Commun.* 365, 355–361. doi:10.1016/j.bbrc.2007.10.194

Ohno-Iwashita, Y., Shimada, Y., Hayashi, M., and Inomata, M. (2010). Plasma Membrane Microdomains in Aging and Disease. *Geriatri. Gerontol. Int.* 10, S41–S52. doi:10.1111/j.1447-0594.2010.00600.x

Oskouian, B. (2006). Sphingosine-1-phosphate Lyase Potentiates Apoptosis via P53 and P38-dependent Pathways and Is Down-Regulated in colon Cancer. *Proc. Natl. Acad. Sci. U. S. A.* 103, 17384–17389. doi:10.1073/pnas.060051013

Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The Role of Autophagy-Lysosome Pathway in Neurodegeneration Associated with Parkinson’s Disease. *Brain* 131, 1969–1978. doi:10.1093/brain/awm318

Panchal, M. (2014). Ceramides and Sphingomyelins in Senile Plaques. *Neurobiol. Dis.* 65, 193–201. doi:10.1016/j.nbd.2014.01.010

Panneer Selvam, S., De Palma, R. M., Oaks, J. J., Oleinik, N., Peterson, Y. K., Stahelin, R. V., et al. (2015). Binding of the Sphingolipid SIP to hTERT Stabilizes Telomerase at the Nuclear Periphery by Alostetiotically Mimicking Protein Phosphorylation. *Sci. Signal.* 8, ra58. doi:10.1126/scisignal.aaa4998

Pardo, A. D., Amico, F., Favelatto, M., Castrataro, R., Fucile, S., Squitieri, F., et al. (2014). FTY720 (Fingolimod) Is a Neuroprotective and Disease-Modifying Agent in Cellular and Mouse Models of Huntington Disease. *Hum. Mol. Genet.* 23, 2251–2265. doi:10.1093/hmg/ddv165

Pardo, A. D., Basit, A., Armiriotti, A., Amico, F., Castaldo, S., Pepe, G., et al. (2017). De Novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington’s Disease. *Front. Neurosci.* 11, 1–10. doi:10.3389/fnins.2017.00698

Pardo, A. D., Castaldo, S., Amico, E., Pepe, G., Marraccino, F., Capocci, L., et al. (2018). Stimulation of S1PR 5 with A-971432, a Selective Agonist, Preserves Blood – Brain Barrier Integrity and Exerts Therapeutic Effect in an Animal Model of Huntington’s Disease. *Hum. Mol. Genet.* 27, 2490–2500. doi:10.1093/hmg/ddy153

Pardo, A. D. (2017). Defective Sphingosine-1-Phosphate Metabolism is a Druggable Target in Huntington’s Disease. *Scientific Rep.* 7, 1–14. doi:10.1038/s41598-017-05799-y

Pardo, A. D. (2020). Neurobiology of Disease Treatment with K6PC-5, a Selective Stimulator of SPHK1, Ameliorates Intestinal Homeostasis in an Animal Model of Huntington’s Disease. *Neurobiol. Dis.* 143, 105090. doi:10.1016/j.nbd.2020.105090

Perks, C. M., Bowman, S., Gill, Z. P., Newcomb, P. V., and Holly, J. M. P. (1999). Differential IGF-independent Effects of Insulin-like Growth Factor Binding Proteins (1–6) on Apoptosis of Breast Epithelial Cells. *J. Cell. Biol.* 75, 652–664. doi:10.1029/2002jd002325

Perry, D. K. (2002). Serine Palmitoyltransferase: Role in Apoptotic De Novo Ceramide Synthesis and Other Stress Responses. *Biochem. Biophys. Acta (BBA) - Mol. Cell Biol Lipids* 1585, 146–152. doi:10.1016/s1388-1981(02)00335-9

Pewzner-Jung, Y., Ben-Dor, S., and Futterman, A. H. (2006). When Do Lasses Die? Defining the Go No-Go Effect of Adenosine A1 Receptor-Mediated Suppression of Intestinal Absorption. *Am. J. Physiol. Gastrointest. Liver Physiol.* 291, G117–G126. doi:10.1152/ajpgi.00103.2005

Phillips, D. C., Hunt, J. T., Monegypney, C. G., Maclean, K. H., McKenzie, P. P., Harris, L. C., et al. (2007). Ceramide-induced G2 Arrest in Rhabdomyosarcoma (RMS) Cells Requires p21Cip1/Waf1 Induction and Is Prevented by MDM2 Overexpression. *Cell Death Differ* 14, 1780–1791. doi:10.1038/sj.jdd.4301928

Pohl, C., and Dikic, I. (2019). Cellular Quality Control by the Ubiquitin-Proteasome System and Autophagy. *Science* 366, 818–822. doi:10.1126/science.aax3769

Proia, R. L., and Hla, T. (2015). Emerging Biology of Sphinogosine-1-Phosphate: Its Role in Pathogenesis and Therapy. *J. Clin. Invest.* 125, 1379–1387. doi:10.1172/jci73639
Volmer, R., Van Der Ploeg, K., and Ron, D. (2013). Membrane Lipid Saturation Activates Endoplasmic Reticulum Unfolded Protein Response Transducers through Their Transmembrane Domains. Proc. Natl. Acad. Sci. 110, 4628–4633. doi:10.1073/pnas.1217611110

Vonsattel, J., and DiFiglia, M. (1998). Huntington Disease. J. Neuropathol. Exp. Neurol. 57, 369–385. doi:10.1097/00005072-199805000-00001

Wakabayashi, K., Tanji, K., Mori, F., and Takahashi, H. (2007). The Lewy Body in Parkinson’s Disease: Molecules Implicated in the Formation and Degradation of α-synuclein Aggregates. Neuropathology 27, 494–506. doi:10.1111/j.1440-1789.2007.00803.x

Weihl, C. C., Pestronk, A., and Kimonis, V. E. (2009). Valosin-containing Protein Disease Inclusion Body Myopathy with Paget’s Disease of the Bone and Fronto-Temporal Dementia. Neuromuscular. Disord. 19, 308–315. doi:10.1016/j.nmd.2009.01.009

Wennberg, A. M. V. (2018). Plasma Sphingolipids Are Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journals Gerontol. - Ser. A. Biol. Sci. Med. Sci. 73, 960–965. doi:10.1093/gerona/glx139

Wong, K. (2004). Neuropathology Provides Clues to the Pathophysiology of Gaucher Disease. Mol. Genet. Metab. 82, 192–207. doi:10.1016/j.ymgme.2004.04.011

Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., et al. (2013). AMPK-dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1. Mol. Cell 49, 1167–1175. doi:10.1016/j.molcel.2013.01.035

Zamora-Pineda, J., Kumar, A., Suh, J. H., Zhang, M., and Saba, J. D. (2016). Dendritic Cell Sphingosine-1-Phosphate Lyase Regulates Thymic Egress. J. Exp. Med. 213, 2773–2791. doi:10.1084/jem.20160287

Zhao, P. (2017). Neuroprotective Effects of Fingolimod in Mouse Models of Parkinson’s Disease. FASEB J. 31, 172–179. doi:10.1096/fj.201600751r

Zhong, Y., Tian, F., Ma, H., Wang, H., Yang, W., Liu, Z., et al. (2020). FTY720 Induces Ferroptosis and Autophagy via PP2A/AMPK Pathway in Multiple Myeloma Cells. Life Sci. 260, 118077. doi:10.1016/j.lfs.2020.118077

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

AD  Alzheimer’s Disease
AkSMase  Alkaline Sphingomyelinase
AMPK  AMP activated protein kinase
APP  Amyloid Precursor Protein
ASAHI  Acid Ceramidase
ASMase  Acid Sphingomyelinase
ATK  Protein Kinase B
ATP  Adenosine Triphosphate
Aβ  Amyloid Beta
C1P  Ceramide-1-Phosphate
CDase  Ceramidases
CerS  Ceramide Synthase
DAG  Diacylglycerol
DDR  DNA Damage Response
DEGS  Dihydroceramide Desaturase
ER  Endoplasmic Reticulum
FA  Fatty Acid
GL  Glycerolipids
GP  Glycerophospholipids
HD  Huntington’s Disease
hTERT  Human Telomerase Reverse Transcriptase
IGF  Insulin Growth Factor
IIS  Insulin/Insulin Like Growth Factor Signaling
LB  Lewy Bodies
LED  Lipid Enriched Diet
mTOR  Mammalian Target of Rapamycin
NSMase  Naturlal Sphingomyelinase
PD  Parkinson’s Disease
PK  polyketides
PKC  Protein Kinase C
PolyQ  Poly Glutamine
PR  Phenol Lipids
Rb  Retinoblastoma Protein
S1P  Sphingosine-1-Phosphate
S1PR  Sphingosine-1-Phosphate Receptor
SaL  Saccharolipids
SASP  Senescent Associated Secretory Phenotype
SK1/2  Sphingosine Kinase
SL  Sphingolipids
SM  Sphingomyelin
SMS  Sphingomyelinase
SPT  Serine Palmitoyltransferase
ST  Sterol Lipids
UPR  Unfolded Protein Response
VCP  Valosine Containing Protein